

LETTER

## Proton pump inhibitor use associated with changes in gut microbiota composition

We read with great interest the recent publications in Gut by Imhann *et al* and Jackson *et al*, which assessed the impact of proton pump inhibitor (PPI) use on gut microbiota diversity and composition in humans.<sup>1,2</sup> PPIs are one of the most commonly used drug classes worldwide. Once initiated, they are often used chronically without clear therapeutic intent.<sup>3</sup> PPIs alter GI pH<sup>4</sup> and delay gastric emptying rate,<sup>5</sup> which could directly affect gut microbiota and survival of enteric pathogens. Using three independent cohorts (211 PPI users and 1604 non-users), Imhann *et al*<sup>1</sup> reported a significant decrease in alpha diversity and changes in 20% of bacterial taxa in PPI users compared with non-users. Among 1827 healthy twins, Jackson *et al*<sup>2</sup> also found a significant decrease in alpha diversity and alteration of bacterial composition in PPI users. Notably, both studies found a higher abundance of oral commensals, including *Streptococcaceae*, among PPI users. These studies controlled for some potential confounders in their analyses; however, intersubject variability could have influenced their results.

We assessed the impact of PPI use on the gut microbiota composition in a prospective study of healthy older adults

(age ≥60 years) from San Antonio, Texas, USA. Participants provided a stool sample at baseline, completed a 14-day course of omeprazole 20mg daily and then provided a follow-up stool sample. Stool 16s rRNA V4 sequences were amplified and sequenced on the Illumina MiSeq platform. Sequences were clustered into operational taxonomic units (OTUs) and classified via mothur's Bayesian classifier referenced against the Greengenes database. Abundance-weighted sample differences were calculated using the Bray-Curtis dissimilarity. PERMANOVA was used to assess the impact of PPI use on beta diversity.

A total of 24 subjects completed the study (mean age 71.4 years and 62.5% women). Mean (±SD) OTU richness was similar between pre-PPI (485±84.3) and post-PPI (496±88.7) samples (p=0.32). Additionally, Shannon diversity was not statistically different between pre-PPI (3.86±0.27) and post-PPI (3.92±0.31) samples (p=0.28). Pre-PPI samples had significantly higher relative abundance of the phylum Actinobacteria and the families *Lachnospiraceae*, *Erysipelotrichaceae* and *Bifidobacteriaceae* (table 1). Post-PPI samples had significantly higher abundance of *Streptococcaceae*. Beta diversity was significantly associated with PPI use (p<0.0001).

In line with our findings, Jackson *et al*<sup>2</sup> found higher *Streptococcaceae* and lower *Lachnospiraceae* and *Erysipelotrichaceae* abundance in PPI users compared

with non-users. Imhann *et al*<sup>1</sup> also noted that PPI users had enrichment for *Streptococcaceae*, but a lower abundance of *Bifidobacteriaceae*. Of note, decreased *Bifidobacterium* is associated with *Clostridium difficile* infection (CDI),<sup>6</sup> whereas supplementation with *Bifidobacterium* is associated with reduced risk of developing CDI in humans.<sup>7</sup> Similarly, the abundance of *Streptococcaceae* is significantly increased in CDI, while *Lachnospiraceae* are reduced compared with healthy controls.<sup>8</sup> While studies have been somewhat inconsistent, a 2012 meta-analysis of 42 studies found that PPI use was associated with an increased risk for initial and recurrent CDI.<sup>9</sup> This led the US Food and Drug Administration to issue a drug safety warning in 2012 regarding this association. Changes in gut microbiota composition could help explain this association. Our findings, in addition to those of Imhann *et al* and Jackson *et al*, highlight the potential for PPIs to affect health through alteration of the gut microbiota and the need to limit inappropriate and unnecessary use of PPIs.

Kelly R Reveles,<sup>1,2</sup> Caitlin N Ryan,<sup>3</sup> Luisa Chan,<sup>3</sup> Reese A Cosimi,<sup>1,4</sup> Wanda L Haynes<sup>5</sup>

<sup>1</sup>College of Pharmacy, The University of Texas at Austin, San Antonio, Texas, USA

<sup>2</sup>Pharmacotherapy Education and Research Center, UT Health San Antonio, San Antonio, Texas, USA

<sup>3</sup>Second Genome, Inc., San Francisco, California, USA

<sup>4</sup>South Texas Veterans Healthcare System, San Antonio, Texas, USA

<sup>5</sup>Institute for Integration of Medicine and Science, UT Health San Antonio, San Antonio, Texas, USA

**Correspondence to** Dr Kelly R Reveles, UT Health San Antonio, Pharmacotherapy Education and Research Center, San Antonio, TX 78229-3900, USA; kdaniels46@utexas.edu

**Acknowledgements** The authors would like to thank the staff at the First Outpatient Research Unit, UT Health San Antonio and at Second Genome, Inc. for their assistance with study procedures. KR would also like to acknowledge the San Antonio Claude D Pepper Older Americans Independence Center's leaders for their invaluable project mentorship: Nicolas Musi, Michael Lichtenstein, Peter Hornsby, Sara Espinoza and Dean Kellogg.

**Contributors** All authors: participated in study design. KRR and WLH: enrolled participants and completed study procedures. CNR and LSC: completed data analysis. All authors participated in data interpretation. KRR: wrote the original manuscript draft and all other authors edited the manuscript.

**Funding** KRR is supported by the National Institutes of Health/National Institute on Aging San Antonio Claude D Pepper Older Americans Independence Center (1P30AG044271-01A1) Career Development (KL2) Program.

**Competing interests** None declared.

**Patient consent** Obtained.

**Ethics approval** UT Health San Antonio.

**Provenance and peer review** Not commissioned; internally peer reviewed.

**Table 1** Comparison of taxa relative abundance in pre-PPI and post-PPI samples

Bacteria*	Pre-PPI mean (SD)	Post-PPI mean (SD)	p Value
Phylum			
Firmicutes	70.70 (10.40)	69.00 (10.40)	0.5531
Bacteroidetes	20.60 (12.30)	24.00 (10.70)	0.0914
Actinobacteria	<b>4.25 (4.76)</b>	<b>2.35 (2.44)</b>	<b>0.0059</b>
Proteobacteria	2.51 (2.96)	3.01 (2.55)	0.2296
Verrucomicrobia	1.14 (4.22)	1.10 (2.80)	0.7726
Euryarchaeota	0.65 (1.75)	0.20 (0.54)	0.3242
Tenericutes	0.13 (0.44)	0.22 (0.71)	0.2708
Cyanobacteria	0.02 (0.08)	0.04 (0.11)	0.4591
Family			
<i>Lachnospiraceae</i>	<b>33.40 (20.50)</b>	<b>28.60 (7.70)</b>	<b>0.0059</b>
<i>Ruminococcaceae</i>	20.50 (9.35)	21.30 (7.98)	0.6373
<i>Bacteroidaceae</i>	13.40 (10.70)	14.90 (9.33)	0.1961
<i>Streptococcaceae</i>	<b>1.49 (1.91)</b>	<b>5.93 (5.30)</b>	<b>0.0009</b>
<i>Prevotellaceae</i>	3.21 (8.23)	4.09 (9.87)	0.6814
<i>Erysipelotrichaceae</i>	<b>4.09 (3.30)</b>	<b>2.74 (3.69)</b>	<b>0.0132</b>
<i>Bifidobacteriaceae</i>	<b>2.83 (4.39)</b>	<b>1.39 (2.09)</b>	<b>0.0275</b>
<i>Rikenellaceae</i>	1.61 (1.23)	2.14 (1.90)	0.0914

Bold values indicate statistical significance at p<0.05.

\*Table includes only the eight most commonly identified phyla and families.

PPI, proton pump inhibitor.

**OPEN ACCESS**

**Open Access** This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.



CrossMark

**To cite** Reveles KR, Ryan CN, Chan L, *et al.* *Gut* Published Online First: [please include Day Month Year]. doi:10.1136/gutjnl-2017-315306

Received 18 September 2017

Revised 25 September 2017

Accepted 27 September 2017

*Gut* 2017;**0**:1–2. doi:10.1136/gutjnl-2017-315306

**REFERENCES**

- 1 Imhann F, Bonder MJ, Vich Vila A, *et al.* Proton pump inhibitors affect the gut microbiome. *Gut* 2016;65:740–8.
- 2 Jackson MA, Goodrich JK, Maxan ME, *et al.* Proton pump inhibitors alter the composition of the gut microbiota. *Gut* 2016;65:749–56.
- 3 Reimer C, Bytzer P. Clinical trial: long-term use of proton pump inhibitors in primary care patients - a cross sectional analysis of 901 patients. *Aliment Pharmacol Ther* 2009;30:725–32.
- 4 O'May GA, Reynolds N, Smith AR, *et al.* Effect of pH and antibiotics on microbial overgrowth in the stomachs and duodena of patients undergoing percutaneous endoscopic gastrostomy feeding. *J Clin Microbiol* 2005;43:3059–65.
- 5 Sanaka M, Yamamoto T, Kuyama Y. Effects of proton pump inhibitors on gastric emptying: a systematic review. *Dig Dis Sci* 2010;55:2431–40.
- 6 Hopkins MJ, Macfarlane GT. Changes in predominant bacterial populations in human faeces with age and with *Clostridium difficile* infection. *J Med Microbiol* 2002;51:448–54.
- 7 Valdés-Varela L, Hernández-Barranco AM, Ruas-Madiedo P, *et al.* Effect of bifidobacterium upon clostridium difficile growth and toxicity when co-cultured in different prebiotic substrates. *Front Microbiol* 2016;7:738.
- 8 Gu S, Chen Y, Zhang X, *et al.* Identification of key taxa that favor intestinal colonization of *Clostridium difficile* in an adult Chinese population. *Microbes Infect* 2016;18:30–8.
- 9 Kwok CS, Arthur AK, Anibueze CI, *et al.* Risk of *Clostridium difficile* infection with acid suppressing drugs and antibiotics: meta-analysis. *Am J Gastroenterol* 2012;107:1011–9.



# Proton pump inhibitor use associated with changes in gut microbiota composition

Kelly R Reveles, Caitlin N Ryan, Luisa Chan, Reese A Cosimi and Wanda L Haynes

*Gut* published online October 9, 2017

---

Updated information and services can be found at:

<http://gut.bmj.com/content/early/2017/10/09/gutjnl-2017-315306>

---

*These include:*

## References

This article cites 9 articles, 3 of which you can access for free at: <http://gut.bmj.com/content/early/2017/10/09/gutjnl-2017-315306#ref-list-1>

## Open Access

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

## Email alerting service

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

---

## Topic Collections

Articles on similar topics can be found in the following collections

[Open access](#) (422)

---

## Notes

---

To request permissions go to:

<http://group.bmj.com/group/rights-licensing/permissions>

To order reprints go to:

<http://journals.bmj.com/cgi/reprintform>

To subscribe to BMJ go to:

<http://group.bmj.com/subscribe/>